Johanson Financial Advisors Inc. Increases Stake in Johnson & Johnson (NYSE:JNJ)
Johanson Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14,438.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,470,520 shares of the company’s stock after acquiring an additional 2,453,527 shares during the quarter. Johnson & Johnson accounts for 0.8% of Johanson Financial Advisors Inc.’s holdings, making the stock its 28th largest position. Johanson Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $16,935,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth approximately $25,000. Financial Advantage Inc. acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $28,000. Kessler Investment Group LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $29,000. Eii Capital Management Inc. acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $39,000. Finally, Permanens Capital L.P. boosted its stake in shares of Johnson & Johnson by 33.3% in the third quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 67.28% of the company’s stock.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $141.07, for a total value of $284,538.19. Following the sale, the executive vice president now owns 51,736 shares in the company, valued at $7,298,397.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hubert Joly bought 5,000 shares of Johnson & Johnson stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same quarter in the previous year, the company posted $2.05 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 8.66 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be given a $0.95 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.62%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
JNJ has been the topic of a number of research analyst reports. Morgan Stanley raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $145.00 to $170.00 in a research note on Tuesday, December 17th. Credit Suisse Group reissued a “buy” rating and set a $163.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Raymond James lowered their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Wells Fargo & Co boosted their price objective on Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, January 9th. Finally, Cantor Fitzgerald started coverage on Johnson & Johnson in a research note on Wednesday, November 27th. They set an “overweight” rating and a $160.00 price objective on the stock. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $159.33.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Inverted Yield Curve
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.